{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:58:56Z","timestamp":1761217136402},"reference-count":0,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2007,11,13]],"date-time":"2007-11-13T00:00:00Z","timestamp":1194912000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nicotinic acid has been in use as a lipid\u2010lowering drug for five decades now. It is effective in lowering low\u2010density lipoprotein (LDL)\u2010cholesterol, triglycerides, and lipoprotein (a), and in increasing high\u2010density lipoprotein (HDL)\u2010cholesterol. All these effects are pronounced, and at present greater increase of HDL\u2010cholesterol cannot be obtained by any other drug. Patients with hypertriglyceridaemia\/low HDL\u2010cholesterol are the most suitable candidates for being treated with this drug. This pattern is typical for type 2 diabetic patients, for patients with metabolic syndrome, and for those with impaired glucose tolerance. From a few studies, there is evidence that nicotinic acid is effective in reducing cardiovascular events. Although overall safety is good, the unpleasant side effect of flushing, albeit not harmful, precludes many patients from taking the drug. New formulations of intermediate release or a combination with anti\u2010flush compounds should increase the compliance with the drug.<\/jats:p>","DOI":"10.1111\/j.1472-8206.2007.00530.x","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T01:19:42Z","timestamp":1195175982000},"page":"5-6","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nicotinic acid in the treatment of hyperlipidaemia"],"prefix":"10.1111","volume":"21","author":[{"given":"Heinz","family":"Drexel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,13]]},"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1472-8206.2007.00530.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1472-8206.2007.00530.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:47:37Z","timestamp":1695815257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1472-8206.2007.00530.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":0,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1111\/j.1472-8206.2007.00530.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1472-8206.2007.00530.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"2007-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}